BOSTON SCIENTIFIC CORP

For the period ended Sep 30, 2025. Filed Nov 3, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 3, 2025

BSX$44.70+1.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Cash Flows (Unaudited)

	Nine Months Ended September 30,
(in millions)	2025	2024
Net income (loss)	$2,222	$1,284
Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities
Depreciation and amortization	1,003	921
Deferred and prepaid income taxes	20	10
Stock-based compensation expense	228	197
Goodwill and other intangible asset impairment charges	46	276
Net loss (gain) on investments and notes receivable	(181)	60
Contingent consideration net expense (benefit)	11	(4)
Inventory step-up amortization	127	—
Fixed asset impairment	73	30
Other, net	22	(8)
Increase (decrease) in operating assets and liabilities, excluding purchase accounting:
Trade accounts receivable	(171)	(261)
Inventories	(138)	(274)
Other assets	(103)	(109)
Accounts payable, accrued expenses and other liabilities	11	(142)
Cash provided by (used for) operating activities	3,170	1,979
Investing activities:
Purchases of property, plant and equipment and internal use software	(525)	(513)
Payments for acquisitions of businesses, net of cash acquired	(1,504)	(1,222)
Payments for investments and acquisitions of certain technologies	(180)	(264)
Proceeds for settlements of hedge contracts	69	—
Other, net	11	17
Cash provided by (used for) investing activities	(2,128)	(1,983)
Financing activities:
Payment of contingent consideration previously established in purchase accounting	(62)	(131)
Payments for finance leases	(49)	(25)
Payments on short-term borrowings	(1,595)	(504)
Net increase (decrease) in commercial paper	(196)	—
Proceeds from long-term borrowings, net of debt issuance costs	1,558	2,145
Cash used to net share settle employee equity awards	(128)	(83)
Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans	262	202
Other, net	(2)	(4)
Cash provided by (used for) financing activities	(211)	1,600
Effect of foreign exchange rates on cash	39	(2)
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents	870	1,594
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period	606	1,055
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period	$1,476	$2,649

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(SUPPLEMENTAL INFORMATION)

	Nine Months Ended September 30,
(in millions)	2025	2024
Supplemental Information
Stock-based compensation expense	$228	$197
Fair value of contingent consideration recorded in purchase accounting	258	29
Right-of-use assets obtained in exchange for finance lease obligations	195	—

	As of September 30,
(in millions)	2025	2024
Reconciliation to amounts within the unaudited consolidated balance sheets:
Cash and cash equivalents	$1,275	$2,502
Restricted cash and restricted cash equivalents included in Other current assets	98	70
Restricted cash equivalents included in Other long-term assets	103	78
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period	$1,476	$2,649

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.